Comment on “Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations”

Tae Hyuk Kim and Jae Hoon Chung from Sungkyunkwan University School of Medicine, Seoul, Korea have reported their experience with adjusted hazard ratio (AHR) for differentiated cancer based on telomerase reverse transcription (TERT) promoter mutations (1). At present, the risk analysis of differentiated thyroid cancer does not consider molecular testing as a major factor. The authors have developed an integrative prognostic system that incorporates TERT promoter mutation into the risk stratification system. This has been used to better categorize and predict outcomes.